Met Life Investment Management, LLC Cardiff Oncology, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 35,726 shares of CRDF stock, worth $121,825. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,726
Previous 26,559
34.52%
Holding current value
$121,825
Previous $115,000
2.61%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
29MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$18.4 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$10.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$8.96 Million0.0% of portfolio
-
Blair William & CO Chicago, IL1.75MShares$5.97 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$4.93 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $148M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...